The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran ...

StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

and OXLUMO for the treatment of primary hyperoxaluria type 1. Receive News & Ratings for Alnylam Pharmaceuticals Daily - ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

After hours: November 29 at 4:05 p.m. EST ...

After hours: 27 November at 18:53 GMT-5 ...

*Pooled data analysis from 22 studies. † Lupus in minorities: nature versus nurture [Unpublished Observ., May 2008]. Lupus occurs only in young women Lupus may occur at any age and in both ...